Product Description
JNJ-40411813 is a positive allosteric modulator of mGluR2 for the treatment of seizures being developed by Addex and Johnson & Johnson. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25735992/)
Mechanisms of Action: MGLUR2/3 Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additional Commercial Interests: Addex Pharma
Clinical Description
Countries in Clinic: Belgium, Germany, Japan, Korea, Poland, Russia, Spain, Ukraine, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Addex presented P2 Epilepsy results on 2024-04-29 for JNJ-40411813
- Clinical Outcomes Reported - Addex announced they will present P2 Epilepsy results in 2Q24 for JNJ-40411813
Highest Development Phases
Phase 2: Seizures
Phase 1: Epilepsy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| jRCT2071200090 | P1 |
Active, not recruiting |
Epilepsy |
2021-05-25 |
|||
| CR108943 | P2 |
Completed |
Seizures |
2024-02-08 |
50% |
2024-03-13 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| A study to investigate JNJ-40411813 in combination with levetiracetam in epilepsy | P2 |
Completed |
Seizures |
2024-02-08 |
50% |
2025-05-27 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/25/2025 |
News Article |
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update |
|
04/17/2025 |
News Article |
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149 |
|
09/30/2024 |
News Article |
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update |
|
07/22/2024 |
News Article |
Addex's Partner Discontinues ADX71149 development in Epilepsy |
|
12/01/2022 |
PubMed |
Current and future pharmacotherapy options for drug-resistant epilepsy. |
|
09/01/2022 |
PubMed |
Clinical investigations of compounds targeting metabotropic glutamate receptors. |
|
03/01/2022 |
PubMed |
Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials. |